MAP2K7 and retinal disorder: This suggests that the development of retinopathy is not restricted to binimetinib, but related to the class of MEK inhibitors.4–8 This retinopathy is thereby most likely to be an on-target effect of MEK inhibition and may reflect the treatment efficacy.